Background: Analysis of prognostic factors for progression-free survival (PFS) and overall survival (OS) was performed using final data from a randomized phase III trial of sunitinib versus interferon-a (IFN-a) as first-line metastatic renal cell carcinoma (RCC) therapy.
introduction
Prognostic factors are utilized in metastatic renal cell carcinoma (RCC) clinical trial design and interpretation, risk-directed treatment, and patient counseling; predictive models have been developed that have been applied to the conduct of clinical trials. One model developed at Memorial Sloan-Kettering Cancer Center (MSKCC) classifies patients as favorable, intermediate, and poor risk according to the number of risk factors predictive of survival [1] . The risk factors related to a shorter survival include time from diagnosis to start of systemic therapy of <1 year, elevated serum lactate dehydrogenase (LDH) levels, high corrected serum calcium levels, anemia, and low performance status. This model was independently validated by investigators at the Cleveland Clinic [2] and used for the study and interpretation of cytokine and targeted drug therapies. Risk grouping guides treatment for a recently proposed nomogram for metastatic RCC [3] . For example, sunitinib or bevacizumab + interferon-a (IFN-a) have been cited as preferred treatment options for metastatic RCC patients with favorable-or intermediate-risk features [3] . In contrast, temsirolimus has been recommended as a preferred treatment option for RCC patients with poor-risk features [3] , based on a large phase III trial that was primarily directed to this patient population [4] .
As sunitinib and other molecularly targeted therapies have become available for use in metastatic RCC, clinical decision making has become more complex, and further information on factors that affect outcomes is needed. In addition, understanding and identifying prognostic factors are important for the development and evaluation of new treatments, e.g. for purposes of stratifying patients in clinical trials and for developing risk groups like the one developed by MSKCC.
Before the advent of targeted therapies, factors predictive for overall survival (OS) were identified for use with cytokine-based therapy in metastatic RCC [1] ; however, their use with sunitinib and other targeted agents has not been fully assessed. Also, in view of recent use of progression-free survival (PFS) as a primary endpoint for clinical trials in metastatic RCC, an assessment of prognostic factors for PFS is warranted. We analyzed final survival data from a randomized phase III trial of sunitinib versus IFN-a [5] to identify new prognostic factors for PFS and OS and to compare them with known factors, such as those comprising the MSKCC risk groups [1] . methods study design, treatment, and patients
In this phase III multicentre study, 750 treatment-naive patients with metastatic RCC were randomized in a 1:1 ratio to receive treatment with either sunitinib malate (SUTENT Ò ; Pfizer, New York, NY) or IFN-a [5, 6] . Key patient eligibility criteria included no previous systemic therapy for RCC, measurable disease, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as well as adequate hepatic, renal, and cardiac functions, and signed informed consent. The primary endpoint was PFS, and full study details and results have been described previously [6] . The study results demonstrated statistically significant improvement in median PFS with sunitinib compared with IFN-a (11 versus 5 months, respectively; P < 0.001), the primary endpoint, and longer median OS (26.4 versus 21.8 months, respectively; P = 0.051) [5] .
statistical methods and analysis
Separate analyses were carried out to identify prognostic factors for investigator-assessed PFS and OS. Prognostic variables investigated in this analysis were based on general review of pretreatment features reported previously. A multivariate Cox regression model was used to analyze potential baseline prognostic variables for each survival measure within the individual treatment arms. All laboratory values were examined as continuous variables. All other baseline factors were examined as binary variables. Each variable was investigated by univariate analysis and then a multivariate analysis was performed with a stepwise algorithm. The algorithm had a type I error of 0.25 for model entry and 0.15 for elimination. Additional elimination was applied to identify significant variables at the level of P <0.05. The analysis explored previously identified prognostic factors, such as those used in the MSKCC risk groups [1] , as well as other factors (Table 1) .
A two-step bootstrap validation was done to validate multivariate analysis results. First, a nonparametric bootstrapping method was used to confirm the variables chosen to be included in the final multivariate models. In the bootstrap procedure, the original dataset of size N becomes a parent population from which samples of size N are randomly drawn with replacement. Three hundred bootstrap samples were created, and a stepwise procedure was applied to each sample using the same significance level for entering and removing a variable as in the original modeling. From these results, the percentage of samples for which each variable was included in the model was calculated. Variables for which percentages were high ( ‡50%) were deemed to provide prognostic value [7] . In the second validation step, 300 bootstrap samples were created and for each of the samples, the final multivariate model was refit and the regression parameter and hazard ratios were estimated. The sample mean and standard deviation of the 300 regression parameters were computed and used to formulate 95% confidence intervals [7] . These estimates were compared with those quantities obtained in the final multivariate models. results patients and treatment administration As previously reported, 375 patients were randomized to each treatment group, and the treatment arms were well balanced with respect to baseline characteristics [6] . The proportion of patients in the favorable-, intermediate-, and poor-risk groups according to MSKCC criteria were 36%, 57%, and 7%, respectively; and the proportions were balanced between arms.
univariate analysis of prognostic factors for PFS and OS
Univariate analysis of baseline clinical characteristics identified a total of 11 and 14 statistically significant predictors of investigator-assessed PFS with sunitinib and IFN-a, respectively (Table 1) . Similarly, univariate analysis identified a total of 14 and 16 statistically significant predictors of OS with sunitinib and IFN-a, respectively ( Table 1) .
The characteristics identified from these analyses included the five prognostic factors from the MSKCC risk groups (performance status, time from diagnosis to treatment, serum LDH level, corrected serum calcium level, and hemoglobin level), as well as other variables. Of note, all five MSKCC prognostic factors were significant predictors of both PFS and OS with sunitinib and IFN-a, except for performance status, which was not a significant predictor for PFS with IFN-a.
multivariate analysis of prognostic factors for PFS and OS
Subsequent multivariate analysis identified five baseline characteristics that were independently predictive for investigator-assessed PFS with sunitinib and seven for IFN-a ( Table 2) . Of the five variables that were significantly predictive of PFS with sunitinib (serum LDH level, the presence of ‡2 metastatic sites, no prior nephrectomy, performance status, and serum platelet count), serum LDH level and the presence of ‡2 metastatic sites were also significant predictors of PFS observed in patients treated on the IFN-a arm.
Additional significant predictors of PFS with IFN-a included the MSKCC risk factors of time from diagnosis to treatment <1 year and hemoglobin level, as well as the presence of lymph node metastases and serum alkaline phosphatase level.
Multivariate analysis found six characteristics that were predictive for OS with sunitinib and eight characteristics predictive for OS with IFN-a ( Table 2 ). In addition to the five MSKCC risk factors, presence of bone metastasis was an additional prognostic factor for OS in the sunitinib treatment arm.
bootstrap validation of prognostic factors
We conducted a validation with 300 bootstrapped datasets to confirm prognostic factors included in each of the multivariate models. After the stepwise procedure was applied to each of the original article Annals of Oncology 300 bootstrapped datasets, the percentage of datasets that included a prognostic factor significant in the final multivariate analysis was calculated.
Serum LDH level, the presence of ‡2 metastatic sites, no prior nephrectomy, performance status, and pretreatment platelet count were significant predictors of PFS for the sunitinib arm with inclusion percents ranging from 46% to 93%. For the IFN-a arm, the percentages of bootstrap samples in which the final multivariate model variables met significance ranged from 54% to 87%.
For OS, all significant predictors for the sunitinib arm could be validated in the multivariate analysis, with inclusion percents ranging from 69% to 100%. For the IFN-a arm, inclusion percents ranged from 70% to 100%. Results from the second step of validation indicated that hazard ratios in the final multivariate models were similar to those obtained in the bootstrap samples.
discussion
Prognostic factors are essential in the design and interpretation of outcome data from clinical trials and for guiding patient care. Reassessment is indicated as therapies, endpoints, and technologies change. Current treatment options include targeted agents (e.g. sunitinib and temsirolimus), combinations of cytokines with targeted agents (i.e. bevacizumab plus IFN-a), and cytokine treatment (high-dose interleukin-2). We performed an analysis to identify and compare prognostic factors for PFS and OS in contemporary patients treated in a phase III clinical trial of sunitinib versus IFN-a as first-line therapy for metastatic RCC.
The results showed that prognostic factors to OS for sunitinib and IFN-a were consistent with those reported previously in the MSKCC model. In the multivariate analysis of OS, five factors were common to the sunitinib and IFN-a Note: for continuous variables, a hazard ratio >1 = risk reduction when the value decreases and a hazard ratio <1 = risk reduction when the value increases; for binary variables (categories in bold), a hazard ratio >1 = risk reduction for the first category and a hazard ratio <1 = risk reduction for the second category. For several laboratory markers, hazard ratios are close to 1 due to the continuous scale of the marker. a Prognostic factors included in Memorial Sloan-Kettering Cancer Center risk groups [1] . IFN-a, interferon-a; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.
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treatment arms: time from diagnosis to treatment, serum LDH level, corrected serum calcium level, hemoglobin level, and the presence of bone metastasis. With the exception of the presence of bone metastasis, five factors identified in sunitinib-treated patients were previously identified in the MSKCC risk groups [1] . Four of these factors were also identified in the IFN-a arm, but ECOG performance status was only predictive for OS in the sunitinib group. One possible reason why ECOG performance status was not identified as a prognostic factor for OS in the IFN-a arm is that the current trial accrued patients with an ECOG performance status of 0 or 1 and the MSKCC risk analysis was based on broader range of performance status according to the Karnofsky scale. Other differences between the treatment arms were identification of the presence of lymph node metastasis and absolute neutrophil count level as prognostic factors in the IFN-a group but not in the sunitinib group. The presence of bone metastasis as a negative prognostic indicator for OS is of interest, although further validation of this finding is required. For both arms, bone metastasis was included in the model 69%-74% of the time in bootstrap validations, indicative of a moderate yet slightly ambiguous relationship with OS. Previous studies have shown mixed results, with the presence of bone metastasis identified as a significant factor in some but not all analyses [1, [8] [9] [10] [11] [12] . For example, in the MSKCC study of 463 patients who received IFN-a, presence of bone metastasis was not found to be a risk factor in either the univariate or the multivariate analysis [1] , while it was highly significant (P < 0.001) in a study of 425 patients given IFN-a and interleukin-2-based treatment that employed a multivariate fractional polynomial algorithm [8] . The reason for this disparity is not clear but may be due in part to differences in the statistical methods used to perform the analyses. Treatment strategies also varied among several studies and may have influenced the significance of particular prognostic variables.
Prior analyses of prognostic factors in metastatic RCC patients have focused on pretreatment clinical features that are linked to OS. The primary endpoint of most recently reported and ongoing clinical trials in metastatic RCC is PFS rather than OS. Therefore, it is important to assess and validate these factors and their prognostic relationship to PFS, particularly Note: for continuous variables, a hazard ratio >1 = risk reduction when the value decreases and a hazard ratio <1 = risk reduction when the value increases; for binary variables (categories in bold), a hazard ratio >1 = risk reduction for the first category and a hazard ratio <1 = risk reduction for the second category. For several laboratory markers, hazard ratios are close to 1 due to the continuous scale of the marker. A recent large retrospective study of prognostic factors for OS in patients receiving vascular endothelial growth factor (VEGF)-targeted agents by Heng et al. [13] identified four of the five MSKCC risk criteria: hemoglobin, corrected calcium, ECOG performance status, and time from diagnosis to treatment. In addition to four of the MSKCC risk factors, Heng et al. reported elevated absolute neutrophil count and elevated pretreatment platelet count as independent predictive factors for OS. In contrast to our findings with sunitinib, neither serum LDH level nor the presence of bone metastasis was identified as prognostic factors for OS in this recently reported study. The differences in clinical variables reported among these two series may reflect the specific factors examined and how they were coded or defined, differences in methodology, and specific patient populations studied. For example, presence of bone metastasis was identified as an independent predictor of shorter survival in our study by univariate and then multivariate analyses. This variable was not examined or uniformly collected in the study by Heng et al. [13] . In addition, since their data were collected retrospectively from participating institutional databases, nearly 20% of patients were missing serum LDH values for analysis. The study by Heng et al. also included patients previously treated with cytokines (one-third of patients) and the patients were treated with various VEGF-targeted therapies [sunitinib (61%), sorafenib (31%), and bevacizumab (8%)]. In comparison, our data were obtained prospectively from patients treated with first-line sunitinib or IFN-a in a phase III clinical trial. Despite these differences, the variables identified in final multivariate analyses were similar, and both studies confirm that the prognostic factors for OS used in the MSKCC risk group stratification system are robust and applicable in the era of targeted therapy. Differences in the risk group distribution from this study versus the original MSKCC risk group publication may reflect eligibility criteria for this phase III trial.
Similarities exist between pretreatment clinical features predictive of OS with targeted therapy and cytokine therapy, as evidenced by both the current study and as reported previously. Therefore, a subgroup of patients with better treatment outcomes with cytokine therapy could not be identified. This suggests that these prognostic factors reflect a relatively nonspecific measure of tumor bulk and aggressiveness rather than a treatment-specific outcome. Continued progress in identification of patient-specific prognostic factors for metastatic RCC will require advances in understanding of tumor biology. One important direction of ongoing research is to identify a molecular signature of response to sunitinib and other targeted agents.
In summary, these results confirm that the prognostic factors used in the MSKCC risk groups are robust and applicable in the contemporary era of targeted therapy. In addition, other factors such as the presence of bone metastases, elevated platelet count or neutrophil count may play a role in prognosis. Clinical trials, based on PFS as the primary endpoint, need to consider that factors predictive of PFS may differ to some degree from those of OS. Continued progress in identification of patient-specific prognostic factors for metastatic RCC will require further advances in the knowledge of tumor-specific biology.
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